Maze Therapeutics, Inc. (MAZE) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Maze Therapeutics, Inc. (MAZE) trades at $28.93 with AI Score 19/100 (Grade F). Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines. Their pipeline targets renal, cardiovascular, metabolic diseases, and obesity. Market cap: $1.60B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026MAZE stock analysis for 2026: Analysts have set a consensus price target of $70.33 for Maze Therapeutics, Inc., suggesting 143.1% upside from the current price of $28.93. The AI MoonshotScore is 19/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MAZE: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Maze Therapeutics, Inc. (MAZE) Healthcare & Pipeline Overview
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in small molecule precision medicines for renal, cardiovascular, and metabolic diseases, including obesity. Their lead programs, MZE829 and MZE782, are currently in Phase II and Phase I clinical trials, respectively, positioning them in a competitive landscape of targeted therapeutics.
What Is the Investment Thesis for MAZE?
Maze Therapeutics, Inc. presents a notable research candidate within the biotechnology sector, driven by its focus on precision medicines targeting genetically defined diseases. The company's lead program, MZE829, targeting APOL1-mediated kidney disease, has the potential to address a significant unmet need in a patient population with limited treatment options. Positive Phase II clinical trial results for MZE829 could serve as a major catalyst, driving significant value. Similarly, the advancement of MZE782 through Phase I clinical trials for chronic kidney disease offers further upside potential. However, the company's high beta of 5.16 indicates significant volatility. Success hinges on clinical trial outcomes and regulatory approvals, making it a high-risk, high-reward investment.
Based on FMP financials and quantitative analysis
MAZE Key Highlights
Market capitalization of $1.60B reflects investor confidence in Maze Therapeutics' pipeline and precision medicine approach.
- MZE829, the lead program, is in Phase II clinical trials, targeting APOL1 kidney disease, a significant milestone in its development.
- MZE782, another key program, is in Phase I clinical trials for chronic kidney disease, expanding the company's therapeutic focus.
- The company's focus on small molecule precision medicines aims to provide more targeted and effective treatments with fewer side effects.
- No dividend yield reflects the company's focus on reinvesting earnings into research and development to advance its pipeline.
Who Are MAZE's Competitors?
MAZE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | $107.79 | -1.04% | $9.36B | — |
| ETON Eton Pharmaceuticals, Inc. | $59.91 | -2.55% | $1.64B | 98 |
| INVA Innoviva, Inc. | $21.13 | +0.62% | $1.56B | 93 |
| LBRX LB Pharmaceuticals Inc | $47.23 | -3.49% | $1.35B | 73 |
| MGTX MeiraGTx Holdings plc | $14.19 | -2.42% | $1.31B | 73 |
| VCEL Vericel Corporation | $42.11 | -3.35% | $2.16B | 93 |
| HRMY Harmony Biosciences Holdings, Inc. | $38.27 | +0.52% | $2.22B | 98 |
| ADMA ADMA Biologics, Inc. | $9.73 | -0.26% | $2.26B | 91 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MAZE's Key Strengths?
Strong focus on precision medicine.
- Proprietary small molecule drug candidates.
- Clinical-stage pipeline with Phase II and Phase I assets.
- Experienced management team.
What Are MAZE's Weaknesses?
Reliance on clinical trial outcomes.
- High cash burn rate associated with drug development.
- Competition from larger pharmaceutical companies.
- Limited commercialization experience.
What Could Drive MAZE Stock Higher?
Phase II clinical trial results for MZE829 in APOL1 kidney disease (expected in 2027).
- Advancement of MZE782 into Phase II clinical trials for chronic kidney disease (expected in 2028).
- Potential for strategic partnerships with pharmaceutical companies.
- Expansion of pipeline into new therapeutic areas.
What Are the Key Risks for MAZE?
Negative return on equity (-36.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for MZE829 or MZE782.
- Regulatory setbacks in obtaining FDA approval.
- Competition from existing therapies and other companies developing precision medicines.
- High cash burn rate associated with drug development.
- Patent challenges to Maze Therapeutics' intellectual property.
What Are the Growth Opportunities for MAZE?
- Expansion of MZE829 into Additional APOL1-Mediated Diseases: Beyond its current focus on APOL1 kidney disease, MZE829 has the potential to address other diseases mediated by APOL1, such as focal segmental glomerulosclerosis (FSGS). The market for FSGS treatment is estimated to reach $1.5 billion by 2030, providing a significant growth opportunity for Maze Therapeutics if MZE829 proves effective in this indication. This expansion could begin following successful Phase II trials, potentially by 2028.
- Advancement of MZE782 into Later-Stage Clinical Trials: The successful completion of Phase I clinical trials for MZE782 in chronic kidney disease (CKD) would pave the way for Phase II and Phase III trials. The global CKD market is projected to reach $20 billion by 2027, offering a substantial market opportunity for Maze Therapeutics. Positive data from these trials could lead to regulatory approval and commercialization by 2030.
- Strategic Partnerships with Pharmaceutical Companies: Maze Therapeutics could pursue strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its pipeline assets. These partnerships could provide access to additional funding, expertise, and resources, accelerating the development and commercialization process. Such partnerships could be initiated as early as 2027, following positive clinical trial data.
- Expansion into New Therapeutic Areas: Maze Therapeutics could leverage its expertise in precision medicine to expand into new therapeutic areas beyond renal, cardiovascular, and metabolic diseases. This could include exploring opportunities in oncology or neurology, where genetically defined diseases are prevalent. The market for precision oncology is expected to reach $100 billion by 2028, presenting a significant growth opportunity. This expansion could begin by 2029, following the establishment of a strong track record in its current focus areas.
- Development of Companion Diagnostics: The development of companion diagnostics to identify patients who are most likely to benefit from Maze Therapeutics' therapies could enhance the effectiveness and adoption of its products. Companion diagnostics can help to personalize treatment and improve patient outcomes. The market for companion diagnostics is projected to reach $8 billion by 2027. Maze could begin developing companion diagnostics for MZE829 and MZE782 by 2027, aligning with the advancement of these programs through clinical trials.
What Are MAZE's Competitive Advantages?
- Proprietary small molecule drug candidates with patent protection.
- Focus on precision medicine targeting specific genetic drivers of disease.
- Clinical trial data demonstrating safety and efficacy.
- Expertise in renal, cardiovascular, and metabolic diseases.
What Does MAZE Do?
Maze Therapeutics, Inc., founded in 2017 and based in South San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to developing small molecule precision medicines. Originally named Modulus Therapeutics, Inc., the company rebranded in September 2018 to Maze Therapeutics, Inc. The company focuses on addressing unmet needs in renal, cardiovascular, and related metabolic diseases, as well as obesity. Maze's approach involves identifying and targeting specific genes and pathways to create therapies that are more effective and have fewer side effects than traditional treatments. Their lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1 (APOL1), which is currently in Phase II clinical trial for patients with APOL1 kidney disease. Additionally, MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, is in Phase I clinical trial for the treatment of chronic kidney disease. These programs highlight Maze's commitment to addressing significant medical needs with innovative, targeted therapies. With a team of 125 employees, Maze Therapeutics is advancing its pipeline and seeking to transform the treatment landscape for complex diseases.
What Products and Services Does MAZE Offer?
- Develop small molecule precision medicines.
- Target renal diseases such as APOL1 kidney disease.
- Address cardiovascular and related metabolic diseases.
- Develop treatments for obesity.
- Conduct Phase II clinical trials for MZE829, an APOL1 inhibitor.
- Conduct Phase I clinical trials for MZE782, an SLC6A19 inhibitor.
How Does MAZE Make Money?
- Develop proprietary small molecule drugs targeting specific genetic pathways.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from the FDA for commercialization.
- Potentially partner with larger pharmaceutical companies for manufacturing and distribution.
What Industry Does MAZE Operate In?
Maze Therapeutics operates in the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for precision medicines is growing, driven by advancements in genomics and personalized healthcare. Companies like Maze are focusing on developing targeted therapies that address specific genetic drivers of disease. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share in specific disease areas. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.
Who Are MAZE's Key Customers?
- Patients with APOL1-mediated kidney disease.
- Patients with chronic kidney disease.
- Individuals with cardiovascular and related metabolic diseases.
- People with obesity.
Key Financial Metrics
Return on equity for Maze Therapeutics, Inc. stands at -36.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 17.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.5%, the inverse of the P/E and a quick read on earnings relative to price.
Maze Therapeutics, Inc. (MAZE) Valuation Context
Valued at $1.60B, MAZE is classified as a small-cap stock. Relative to its peer group, MAZE's quantitative score of 19/100 is below the peer average of 84/100.
Company Profile
Maze Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Jason Coloma. MAZE has traded publicly since 2025.
Financial Health
Maze Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 10.77 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Maze Therapeutics, Inc. has missed Wall Street's EPS estimate in 4 of its last 7 reported quarters — a mixed record worth weighing. Reported results have landed about 601.2% below estimates on average.
Forward Outlook
Wall Street analysts project Maze Therapeutics, Inc. revenue of about $20.0M for fiscal 2026, with EPS near $-2.76. The estimate reflects 9 contributing analysts.
MAZE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong focus on precision medicine.
- Proprietary small molecule drug candidates.
- Clinical-stage pipeline with Phase II and Phase I assets.
- Experienced management team.
Bear Case
- Reliance on clinical trial outcomes.
- High cash burn rate associated with drug development.
- Competition from larger pharmaceutical companies.
- Limited commercialization experience.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20M | -$24M | -$0.45 |
Based on FMP financials and quantitative analysis
MAZE Latest News
No recent news available for MAZE.
MAZE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MAZE.
Price Targets
Consensus target: $70.33
MAZE MoonshotScore
What does this score mean?
The MoonshotScore rates MAZE 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jason V. Coloma
CEO
Jason V. Coloma serves as the CEO of Maze Therapeutics, bringing extensive experience in the biopharmaceutical industry. Prior to Maze, he held leadership positions at various biotech companies, focusing on drug discovery and development. His background includes a strong scientific foundation and a track record of successfully advancing novel therapies through clinical trials. Coloma's expertise spans multiple therapeutic areas, including renal, cardiovascular, and metabolic diseases. He is known for his strategic vision and ability to build high-performing teams.
Track Record: Under Jason V. Coloma's leadership, Maze Therapeutics has advanced its lead programs, MZE829 and MZE782, into Phase II and Phase I clinical trials, respectively. He has overseen significant fundraising efforts to support the company's research and development activities. Coloma has also fostered a culture of innovation and collaboration within the organization, attracting top talent to drive the company's mission forward.
Maze Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for MAZE?
MAZE holds an AI Score of 19/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines. Their pipeline targets renal, cardiovascular, metabolic diseases, and obesity.
What does Maze Therapeutics, Inc. do?
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity. Their approach involves targeting specific genes and pathways to create therapies that are more effective and have fewer side effects than traditional treatments.
What do analysts say about MAZE stock?
Analyst coverage of Maze Therapeutics, Inc. is evolving as the company progresses through clinical trials. Current sentiment reflects cautious optimism, with a focus on the potential of MZE829 and MZE782 to address unmet needs in their respective disease areas. Valuation metrics are heavily influenced by the projected success rates of these clinical programs and the potential market size.
What are the main risks for MAZE?
The primary risks for Maze Therapeutics, Inc. revolve around the inherent uncertainties of clinical drug development. Clinical trial failures for MZE829 or MZE782 could significantly impact the company's valuation. Regulatory setbacks in obtaining FDA approval also pose a threat. Additionally, competition from existing therapies and other companies developing precision medicines could limit market share.
What are the key factors to evaluate for MAZE?
Maze Therapeutics, Inc. (MAZE) holds an AI score of 19/100 (low). Analysts target $70.33 (+143%). presents a notable research candidate within the biotechnology sector, driven by its focus on precision medicines targeting genetically defined diseases. Not financial advice.
How frequently does MAZE data refresh on this page?
MAZE's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MAZE's recent stock price performance?
Maze Therapeutics, Inc. (MAZE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong focus on precision medicine. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MAZE overvalued or undervalued right now?
Maze Therapeutics, Inc. (MAZE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $70.33 (+143%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MAZE before investing?
Before investing in Maze Therapeutics, Inc. (MAZE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10.
- Clinical trial outcomes are inherently uncertain and can significantly impact the company's prospects.